Dozens of hospitals, health departments and public health officials all over the country have put out easily disprovable statements claiming a rise in RSV cases. (Related: Fauci, mainstream media claim "triple threat" of viruses coming this winter.)
These claims are supported by the Centers for Disease Control and Prevention (CDC) and prominent health officials like Dr. Anthony Fauci, who have been sounding the alarm for a looming "tripledemic" of RSV, influenza and the Wuhan coronavirus (COVID-19).
In Southern California, the health department for Orange County declared a local health emergency over an alleged rise in the number of pediatric RSV cases. Dr. Regina Chinsio-Kwong, the county's health officer, claimed in a press release that the declaration was issued due to "rapidly spreading virus infections causing record numbers of pediatric hospitalizations and daily emergency room visits."
But Rita Barnett-Rose, a California-based attorney, noted that there is no evidence to support any official claims coming out of Orange County, especially from hospitals claiming they are overextended.
Barnett-Rose said hospitals in the county are overextended not due to a high number of admissions, but due to low staffing caused by the firing of unvaccinated employees.
This claim is supported by local reporters and healthcare workers who pointed out that there were not enough pediatricians and other kinds of medical professionals in the county, leading to county health officials looking oversees for more health workers.
Pfizer, GSK seek control of RSV vaccine market
Perhaps of bigger concern is the current Big Pharma race between GSK and Pfizer to get their in-development RSV vaccines approved. Either company could see the first-ever approvals for an RSV vaccine by mid-to-late 2023.
GSK already has a priority review and a May 3 approval action date for its RSV vaccine, which is targeted toward older adults. Pfizer isn't far behind with its RSV vaccine that targets pregnant women with an eye toward protecting their children as soon as they are born.
Competition between the two Big Pharma companies is increasing, as can be seen from statements made by their top executives during their third-quarter earnings calls.
GSK CEO Emma Walmsley said the company "intends to be competitive" with its late-stage RSV vaccine, which it has "very high confidence" in. The company feels that it can easily out-compete Pfizer in this new market.
Pfizer Chief Scientific Officer Dr. Mikael Dolsten noted that the efficacy of both vaccines look somewhat similar, but "if you look at our tolerability, [it] was among the best vaccines you ever can see."
GSK was hoping to market its vaccine for both infants and people aged 60 and older, but safety concerns during vaccine trials forced it to scrap these plans and opt instead for the vaccine to just be targeted toward adults.
Meanwhile, Pfizer is hoping to go to the Food and Drug Administration (FDA) to get approval for its maternal-use RSV vaccine to be extended to all adults by year's end. The company claims that phase 3 trials in infants showed very positive results, strongly suggesting that the vaccine could also be given to children under five.
Other prominent Big Pharma players are also looking at getting into the RSV vaccine market but are further back in their respective vaccine development cycles.
Moderna has an mRNA candidate that has just entered phase 3 testing. AstraZeneca and Sanofi are working together to develop a long-acting antibody designed to supposedly protect all infants against RSV from birth through their first RSV season with a single dose. AstraZeneca and Sanofi are expected to file an application to the FDA by the end of the year.
Watch this clip from "The HighWire" with Del Bigtree and co-host Jefferey Jaxen as they discuss how the RSV being seen outside its normal seasonal window is leaving more questions than answers.
This video is from the High Hopes channel on Brighteon.com.
More related stories:
First RSV emergency declared as Pfizer and GSK race to get vaccines approved.
Sources include:
Please contact us for more information.
